Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Part of paid clinical trials in Richmond, Virginia.
- Sponsor
- Virginia Commonwealth University
- Study ID
- NCT07700225
- Status
- Recruiting
Conditions
- DM1
- Myotonic Dystrophy
- Myotonic Dystrophy 1
- Myotonic Dystrophy Type 1
- Myotonic Dystrophy Type-1
- Myotonic Dystrophy, Type 1 (DM1)
- Myotonic Muscular Dystrophy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Study Details
Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy. It is characterized by progressive weakness and myotonia, which preferentially affects the craniofacial, hand, and distal leg muscles. Many patients also experience difficulties with cognition, cardiac arrhythmias, respiratory failure, or cataracts. Currently there is no treatment to slow progression or reverse the symptoms.
Key Dates
- First listed
- Jul 13, 2026
- Start date
- Jul 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2032
- Completion
- Dec 31, 2032
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: Myotonic Dystrophy Type 1 (DM1) Longitudinal CohortParticipants with a clinical or genetic diagnosis of myotonic dystrophy type 1 (DM1) or congenital myotonic dystrophy (CDM). This cohort includes individuals transitioning from the parent study, Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1; NCT03981575), as well as newly enrolled participants.
Primary Outcome Measure
Characterize the long-term disease progression- 10 meter walk/run [ Time Frame: Baseline (0 months), every 12 months over four years ]
Central Contacts
- Jennifer Raymond804-828-6318
- Ruby Langeslay804-828-6318
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Nicholas Johnson, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Richmond, VA
By research site
Related Studies
- Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)Recruiting · Virginia Commonwealth University · La Jolla, California
- Study of ATX-01 in Participants With DM1PHASE1/PHASE2 · Recruiting · ARTHEx Biotech S.L. · Los Angeles, California
- Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy ExtensionRecruiting · Virginia Commonwealth University · Richmond, Virginia
- A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1PHASE1/PHASE2 · Recruiting · Sanofi · Gainesville, Florida